{
    "info": {
        "nct_id": "NCT03531918",
        "official_title": "A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm",
        "inclusion_criteria": "* Diagnosis of untreated \"high-grade\" myeloid neoplasm (≥ 10% blasts in blood or bone marrow) or acute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2016 World Health Organization (WHO) classification; outside diagnostic material is acceptable to establish diagnosis; submission of peripheral blood specimen for flow cytometry performed at the study institution should be considered; diagnostic material must have been submitted for cytogenetic and/or molecular testing as clinically appropriate\n* Medically fit, as defined by treatment-related mortality (TRM) score ≤13.1 calculated with simplified model\n* The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment\n* Patients may have received low-intensity treatment (e.g. azacitidine/decitabine, lenalidomide, growth factors) for antecedent low-grade myeloid neoplasm (i.e. < 10% blasts in blood and bone marrow)\n* Bilirubin ≤ 2.5 x institutional upper limit of normal (IULN) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis (assessed within 14 days prior to study day 0)\n* Serum creatinine ≤ 2.0 mg/dL (assessed within 14 days prior to study day 0)\n* Left ventricular ejection fraction ≥ 45%, assessed within 12 months prior to study day 0, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure\n* Women of childbearing potential and men must agree to use adequate contraception\n* Provide written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Myeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatment\n* Concomitant illness associated with a likely survival of < 1 year\n* Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials, and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. known chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligible\n* Known hypersensitivity to any study drug\n* Confirmed or suspected pregnancy or active breast feeding\n* Treatment with any other investigational anti-leukemia agent; in phase 2, treatment with a tyrosine kinase inhibitor for patients with FLT3-mutated AML is permissible",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "use of hydroxyurea prior to study registration is allowed",
                    "criterion": "hydroxyurea use prior to study registration",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with symptoms/signs of hyperleukocytosis",
                    "criterion": "symptoms/signs of hyperleukocytosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "white blood cells (WBC) > 100,000/uL",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100000,
                                "unit": "uL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "can be treated with leukapheresis",
                    "criterion": "leukapheresis treatment prior to enrollment",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment",
                    "criterion": "cytarabine administration prior to enrollment",
                    "requirements": [
                        {
                            "requirement_type": "maximum number of doses",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "doses"
                            }
                        },
                        {
                            "requirement_type": "maximum dose per administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 500,
                                "unit": "mg/m^2/dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine ≤ 2.0 mg/dL (assessed within 14 days prior to study day 0)",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 2.0 mg/dL (assessed within 14 days prior to study day 0)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "assessment timing",
                            "expected_value": "within 14 days prior to study day 0"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential and men must agree to use adequate contraception",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential",
                    "criterion": "childbearing potential (female)",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use adequate contraception",
                    "criterion": "contraception use agreement",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "men must agree to use adequate contraception",
                    "criterion": "contraception use agreement (male)",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Medically fit, as defined by treatment-related mortality (TRM) score ≤13.1 calculated with simplified model",
            "criterions": [
                {
                    "exact_snippets": "treatment-related mortality (TRM) score ≤13.1 calculated with simplified model",
                    "criterion": "treatment-related mortality (TRM) score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 13.1,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "simplified model"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction ≥ 45%, assessed within 12 months prior to study day 0, e.g. by multigated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction ≥ 45%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "assessment_timeframe",
                            "expected_value": "within 12 months prior to study day 0"
                        }
                    ]
                },
                {
                    "exact_snippets": "no clinical evidence of congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "clinical evidence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin ≤ 2.5 x institutional upper limit of normal (IULN) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis (assessed within 14 days prior to study day 0)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ≤ 2.5 x institutional upper limit of normal (IULN)",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x IULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis",
                    "criterion": "cause of elevated bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": [
                                "hepatic infiltration by AML",
                                "Gilbert's syndrome",
                                "hemolysis"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "assessed within 14 days prior to study day 0",
                    "criterion": "bilirubin assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "assessment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to study day 0"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of untreated \"high-grade\" myeloid neoplasm (≥ 10% blasts in blood or bone marrow) or acute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2016 World Health Organization (WHO) classification; outside diagnostic material is acceptable to establish diagnosis; submission of peripheral blood specimen for flow cytometry performed at the study institution should be considered; diagnostic material must have been submitted for cytogenetic and/or molecular testing as clinically appropriate",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of untreated \"high-grade\" myeloid neoplasm (≥ 10% blasts in blood or bone marrow)",
                    "criterion": "high-grade myeloid neoplasm",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "blast percentage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "blast location",
                            "expected_value": [
                                "blood",
                                "bone marrow"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "acute myeloid leukemia (AML) other than acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants according to the 2016 World Health Organization (WHO) classification",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) or variants"
                        },
                        {
                            "requirement_type": "classification",
                            "expected_value": "2016 WHO"
                        }
                    ]
                },
                {
                    "exact_snippets": "outside diagnostic material is acceptable to establish diagnosis",
                    "criterion": "diagnostic material origin",
                    "requirements": [
                        {
                            "requirement_type": "acceptability",
                            "expected_value": "outside material acceptable"
                        }
                    ]
                },
                {
                    "exact_snippets": "submission of peripheral blood specimen for flow cytometry performed at the study institution should be considered",
                    "criterion": "peripheral blood specimen for flow cytometry",
                    "requirements": [
                        {
                            "requirement_type": "submission",
                            "expected_value": "should be considered"
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "study institution"
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnostic material must have been submitted for cytogenetic and/or molecular testing as clinically appropriate",
                    "criterion": "diagnostic material submission for cytogenetic and/or molecular testing",
                    "requirements": [
                        {
                            "requirement_type": "submission",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "testing type",
                            "expected_value": [
                                "cytogenetic",
                                "molecular"
                            ]
                        },
                        {
                            "requirement_type": "clinical appropriateness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Provide written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Provide written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provided",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "format",
                            "expected_value": "written"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients may have received low-intensity treatment (e.g. azacitidine/decitabine, lenalidomide, growth factors) for antecedent low-grade myeloid neoplasm (i.e. < 10% blasts in blood and bone marrow)",
            "criterions": [
                {
                    "exact_snippets": "Patients may have received low-intensity treatment (e.g. azacitidine/decitabine, lenalidomide, growth factors)",
                    "criterion": "prior low-intensity treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "azacitidine",
                                "decitabine",
                                "lenalidomide",
                                "growth factors"
                            ]
                        },
                        {
                            "requirement_type": "allowed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "antecedent low-grade myeloid neoplasm (i.e. < 10% blasts in blood and bone marrow)",
                    "criterion": "antecedent low-grade myeloid neoplasm",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "< 10% blasts in blood and bone marrow",
                    "criterion": "blast percentage in blood and bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials, and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired [e.g. known chronic viral hepatitis, human immunodeficiency virus (HIV)]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligible",
            "criterions": [
                {
                    "exact_snippets": "Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials, and/or controlled or stable",
                    "criterion": "active systemic infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": [
                                "under treatment with anti-microbials",
                                "controlled",
                                "stable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours",
                    "criterion": "clinical stability",
                    "requirements": [
                        {
                            "requirement_type": "afebrile_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "hemodynamic_stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 24,
                                "unit": "hours"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with fever thought to be likely secondary to leukemia are eligible",
                    "criterion": "fever etiology",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "secondary to leukemia"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed or suspected pregnancy or active breast feeding",
            "criterions": [
                {
                    "exact_snippets": "Confirmed or suspected pregnancy",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "confirmed",
                                "suspected"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "active breast feeding",
                    "criterion": "breast feeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with any other investigational anti-leukemia agent; in phase 2, treatment with a tyrosine kinase inhibitor for patients with FLT3-mutated AML is permissible",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any other investigational anti-leukemia agent",
                    "criterion": "treatment with investigational anti-leukemia agent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "in phase 2, treatment with a tyrosine kinase inhibitor for patients with FLT3-mutated AML is permissible",
                    "criterion": "treatment with tyrosine kinase inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "permissibility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "phase",
                            "expected_value": "phase 2"
                        },
                        {
                            "requirement_type": "disease subtype",
                            "expected_value": "FLT3-mutated AML"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to any study drug",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any study drug",
                    "criterion": "hypersensitivity to study drug",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Concomitant illness associated with a likely survival of < 1 year",
            "criterions": [
                {
                    "exact_snippets": "Concomitant illness associated with a likely survival of < 1 year",
                    "criterion": "concomitant illness with likely survival",
                    "requirements": [
                        {
                            "requirement_type": "expected survival",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatment",
            "criterions": [
                {
                    "exact_snippets": "Myeloid blast crisis of chronic myeloid leukemia (CML)",
                    "criterion": "myeloid blast crisis of chronic myeloid leukemia (CML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless patient is not considered candidate for tyrosine kinase inhibitor treatment",
                    "criterion": "candidate for tyrosine kinase inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "candidate status",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}